Closing on Nov. 3: Investor Calendar + Company Spotlight

INVESTOR NETWORK is the go-to, one-stop site for shareholders, clients and prospective investors


Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

Covidien Celebrates Successful Separation of Pharmaceuticals Business

Executives and guests of Dublin-based Covidien will visit the New York Stock Exchange (NYSE) to celebrate the successful spinoff of its Mallinckrodt pharmaceuticals business. (NYSE: MNK). To mark this occasion, José (Joe) E. Almeida, Chairman, President and Chief Executive Officer of Covidien plc, will ring The NYSE Closing Bell, joined by members of the company's management team. Covidien will complete the distribution of Mallinckrodt ordinary shares after the close of trading on the NYSE on June 28, 2013. On July 1, 2013, regular-way trading will commence on the NYSE for Mallinckrodt under the symbol "MNK" and will continue for Covidien under the symbol "COV." ABOUT COVIDIEN (NYSE: COV) Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit to learn more about our business.

Covidien Plc video

Covidien Celebrates Successful Separation of Pharmaceuticals Business

Covidien Plc video


Covidien Plc video

Covidien Revascularization Device Receives FDA Clearance


José E. Almeida, Chairman, President and Chief Executive Officer
José (Joe) E. Almeida has been the President, Chief Executive Officer and a Director of Covidien plc since July 2011. Mr. Almeida became Chairman of the Board of Directors in March 2012.
Prior to being elected President and CEO, Mr. Almeida was President of the Medical Devices segment of Covidien. In this position, Mr. Almeida oversaw the Surgical Devices, Energy-based Devices, Respiratory & Monitoring Solutions and Vascular Therapies Global Business Units, as well as the Japan, Asia, Canada and Latin America regions. These businesses account for approximately two-thirds of the Company’s total annual revenues and about three-quarters of its operating profit.
Mr. Almeida joined Covidien (formerly known as Tyco Healthcare) in 1995 as Director of Manufacturing and Corporate Engineering, and then held several positions of increasing responsibility, including Vice President of European Manufacturing and Vice President of Global Manufacturing.
Mr. Almeida left Covidien in 2003 for Greatbatch Technologies, Inc., a leading manufacturer of power sources and components for implantable medical devices, before returning to Covidien in 2004 as President of the International Business Unit.
Before joining Covidien, Mr. Almeida was a Director of Manufacturing in American Home Products’ Acufex Microsurgical division, an Engineering Manager of Johnson & Johnson’s Professional Products division and a Management Consultant at Andersen Consulting (Accenture).
Mr. Almeida received a Bachelor’s degree from Escola de Engenharia Maua in São Paulo, Brazil. He currently serves on the Board of Directors of Advanced Medical Technology Association (AdvaMed).
Charles J. Dockendorff, Chief Financial Officer
Charles J. Dockendorff is Executive Vice President and Chief Financial Officer (CFO) of Covidien plc, a position he has held since 1995.
In this position, Mr. Dockendorff is responsible for the Company’s financial management and activities, including Corporate Accounting, Tax, Treasury, Financial Planning and Investor Relations, as well as Internal Audit and Information Services. The financial leadership for Covidien’s three business segments also report to him.
Mr. Dockendorff joined the Kendall Healthcare Products Company, the foundation of the Covidien (formerly known as Tyco Healthcare) business, in 1989 as Controller and he was named Vice President and Controller of Kendall in 1994. In 1995, Mr. Dockendorff was appointed CFO of Covidien and helped the Company grow from $600 million in sales to the diverse $10 billion healthcare products leader it is today.
Before joining Covidien and its predecessors, Mr. Dockendorff was the CFO, Vice President of Finance and Treasurer of Epsco, Inc. and the CFO of Infrared Industries, Inc. In addition, Mr. Dockendorff worked as an accountant for Arthur Young & Company (now Ernst & Young) and the General Motors Corporation.
A Certified Public Accountant, Mr. Dockendorff has a Bachelor’s degree in Business Administration/Accounting from the University of Massachusetts and a Master of Science degree in Finance from Bentley College (Massachusetts).
Bryan C. Hanson, Group President
Bryan C. Hanson is Group President of Covidien plc, a position he has held since July 2011.
In this position, Mr. Hanson is responsible for the Surgical Devices and Energy-based Devices businesses, including the endomechanical, soft tissue repair and energy product lines.
Prior to being named Group President, Mr. Hanson was President, Energy-based Devices. Since joining the Company in 1992, he has successfully developed and implemented marketing and sales strategies, business review systems, infrastructures and cost reduction programs. Mr. Hanson has held positions of increasing responsibility in sales, marketing and general management, in the vascular therapy and medical supplies groups as well as the international business.
Mr. Hanson holds a Bachelor of Science degree in Finance from Florida State University.

News & Analysis

You may also be interested in: